{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T18:10:59Z","timestamp":1785607859481,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Medical Education Collaborative Innovation Fund of Jiangsu University","award":["JDYY2023076"],"award-info":[{"award-number":["JDYY2023076"]}]},{"name":"Changzhou Science and Technology Project Fund","award":["CJ20230005"],"award-info":[{"award-number":["CJ20230005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10557-025-07706-0","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T04:40:05Z","timestamp":1746592805000},"page":"517-529","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The FUNCTION Study: A Randomized Controlled Trial on the Efficacy of Sacubitril\/Valsartan on the Success Rate of Catheter Ablation for Nonparoxysmal Atrial Fibrillation"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5496-0435","authenticated-orcid":false,"given":"Wenhua","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixiang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheliang","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"issue":"38","key":"7706_CR1","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893\u2013962. https:\/\/doi.org\/10.1093\/eurheartj\/ehw210","journal-title":"Eur Heart J"},{"issue":"2","key":"7706_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/1747493019897870","volume":"16","author":"G Lippi","year":"2021","unstructured":"Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217\u201321. https:\/\/doi.org\/10.1177\/1747493019897870","journal-title":"Int J Stroke"},{"issue":"6","key":"7706_CR3","doi-asserted-by":"publisher","first-page":"844","DOI":"10.3390\/ph16060844","volume":"16","author":"J Kingma","year":"2023","unstructured":"Kingma J, Simard C, Drolet B. Overview of cardiac arrhythmias and treatment strategies. Pharmaceuticals (Basel). 2023;16(6):844. https:\/\/doi.org\/10.3390\/ph16060844.","journal-title":"Pharmaceuticals (Basel)."},{"issue":"FI_3","key":"7706_CR4","doi-asserted-by":"publisher","first-page":"f366","DOI":"10.1093\/europace\/eux297","volume":"20","author":"JA Clarnette","year":"2018","unstructured":"Clarnette JA, Brooks AG, Mahajan R, et al. Outcomes of persistent and long-standing persistent atrial fibrillation ablation: a systematic review and meta-analysis. Europace. 2018;20(FI_3):f366\u201376. https:\/\/doi.org\/10.1093\/europace\/eux297","journal-title":"Europace."},{"issue":"1","key":"7706_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1161\/CIRCEP.107.754564","volume":"1","author":"S Nattel","year":"2008","unstructured":"Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol. 2008;1(1):62\u201373. https:\/\/doi.org\/10.1161\/CIRCEP.107.754564","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"22","key":"7706_CR6","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.jacc.2014.02.555","volume":"63","author":"S Nattel","year":"2014","unstructured":"Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2014;63(22):2335\u201345. https:\/\/doi.org\/10.1016\/j.jacc.2014.02.555","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"7706_CR7","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.3390\/biomedicines11123261","volume":"11","author":"RE Mitran","year":"2023","unstructured":"Mitran RE, Popa-Fotea NM, Iorgulescu C, et al. Left atrial low-voltage areas predict the risk of atrial fibrillation recurrence after radiofrequency ablation. Biomedicines. 2023;11(12):3261. https:\/\/doi.org\/10.3390\/biomedicines11123261","journal-title":"Biomedicines"},{"issue":"11","key":"7706_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.117.005405","volume":"10","author":"B Yang","year":"2017","unstructured":"Yang B, Jiang C, Lin Y, et al. STABLE-SR (electrophysiological substrate ablation in the left atrium during sinus rhythm) for the treatment of nonparoxysmal atrial fibrillation: a prospective, multicenter randomized clinical trial. Circ Arrhythm Electrophysiol. 2017;10(11): e005405. https:\/\/doi.org\/10.1161\/CIRCEP.117.005405","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"4","key":"7706_CR9","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/europace\/euy313","volume":"21","author":"KN Lee","year":"2019","unstructured":"Lee KN, Choi JI, Kim YG, et al. Comparison between linear and focal ablation of complex fractionated atrial electrograms in patients with non-paroxysmal atrial fibrillation: a prospective randomized trial. Europace. 2019;21(4):598\u2013606. https:\/\/doi.org\/10.1093\/europace\/euy313","journal-title":"Europace"},{"issue":"7","key":"7706_CR10","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1161\/CIRCULATIONAHA.113.005421","volume":"130","author":"M Haissaguerre","year":"2014","unstructured":"Haissaguerre M, Hocini M, Denis A, et al. Driver domains in persistent atrial fibrillation. Circulation. 2014;130(7):530\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.005421","journal-title":"Circulation"},{"key":"7706_CR11","doi-asserted-by":"publisher","unstructured":"China International Exchange and Promotive Association for Medical and Health Care Hypertension Branch, Chinese Medical Association Cardiovascular Branch, China Hypertension League, and the Expert Panel on \"Angiotensin Receptor Neprilysin Inhibitors\" Recommendations. Chinese expert recommendation on the clinical application of sacubactril valsartan in patients with hypertension. Chin J Hypertens. 2021;29(2):108\u2013114. https:\/\/doi.org\/10.16439\/j.issn.1673-8245.2021.02.003","DOI":"10.16439\/j.issn.1673-8245.2021.02.003"},{"issue":"18","key":"7706_CR12","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145(18):e895\u20131032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"issue":"19","key":"7706_CR13","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1016\/j.jacc.2018.07.102","volume":"72","author":"J Torrado","year":"2018","unstructured":"Torrado J, Cain C, Mauro AG, et al. Sacubitril\/valsartan averts adverse post-infarction ventricular remodeling and preserves systolic function in rabbits. J Am Coll Cardiol. 2018;72(19):2342\u201356. https:\/\/doi.org\/10.1016\/j.jacc.2018.07.102","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"7706_CR14","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/s00392-019-01440-y","volume":"108","author":"P Martens","year":"2019","unstructured":"Martens P, Nuyens D, Rivero-Ayerza M, et al. Sacubitril\/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction. Clin Res Cardiol. 2019;108(10):1074\u201382. https:\/\/doi.org\/10.1007\/s00392-019-01440-y","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"7706_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005565","volume":"12","author":"RM Burke","year":"2019","unstructured":"Burke RM, Lighthouse JK, Mickelsen DM, Small EM. Sacubitril\/valsartan decreases cardiac fibrosis in left ventricle pressure overload by restoring PKG signaling in cardiac fibroblasts. Circ Heart Fail. 2019;12(4):e005565. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.118.005565","journal-title":"Circ Heart Fail"},{"key":"7706_CR16","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.3389\/fphar.2019.01285","volume":"10","author":"Y Suo","year":"2019","unstructured":"Suo Y, Yuan M, Li H, et al. Sacubitril\/valsartan improves left atrial and left atrial appendage function in patients with atrial fibrillation and in pressure overload-induced mice. Front Pharmacol. 2019;10:1285. https:\/\/doi.org\/10.3389\/fphar.2019.01285","journal-title":"Front Pharmacol"},{"issue":"13","key":"7706_CR17","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.015927","volume":"9","author":"M Masuda","year":"2020","unstructured":"Masuda M, Asai M, Iida O, et al. Additional low-voltage-area ablation in patients with paroxysmal atrial fibrillation: results of the randomized controlled VOLCANO trial. J Am Heart Assoc. 2020;9(13): e015927. https:\/\/doi.org\/10.1161\/JAHA.120.015927","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"7706_CR18","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10557-022-07315-1","volume":"37","author":"Q Wang","year":"2023","unstructured":"Wang Q, Zhuo C, Xia Q, et al. Sacubitril\/valsartan can reduce atrial fibrillation recurrence after catheter ablation in patients with persistent atrial fibrillation. Cardiovasc Drugs Ther. 2023;37(3):549\u201360. https:\/\/doi.org\/10.1007\/s10557-022-07315-1","journal-title":"Cardiovasc Drugs Ther"},{"key":"7706_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173120","volume":"881","author":"LYF Li","year":"2020","unstructured":"Li LYF, Lou Q, Liu GZ, Lv JC, Li WM. Sacubitril\/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation. Eur J Pharmacol. 2020;881: 173120. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173120","journal-title":"Eur J Pharmacol"},{"key":"7706_CR20","doi-asserted-by":"publisher","first-page":"932780","DOI":"10.3389\/fcvm.2022.932780","volume":"9","author":"YZ Dong","year":"2022","unstructured":"Dong YZ, Xiao SC, He JW, et al. Angiotensin receptor-neprilysin inhibitor therapy and recurrence of atrial fibrillation after radiofrequency catheter ablation: a propensity-matched cohort study. Front Cardiovasc Med. 2022;9:932780. https:\/\/doi.org\/10.3389\/fcvm.2022.932780","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"7706_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/FJC.0000000000001537","volume":"83","author":"S Luigi","year":"2024","unstructured":"Luigi S, Carlo G, Giuseppe BZ, et al. Catalysts of cardiovascular electromechanical harmony? Unveiling the impact of RAS INHIBITORS and ARNI on atrial fibrillation recurrence after ablation. J Cardiovasc Pharmacol. 2024;83(3):228\u201330. https:\/\/doi.org\/10.1097\/FJC.0000000000001537","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"7706_CR22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.hrthm.2024.01.053","volume":"21","author":"ML Yasuharu","year":"2024","unstructured":"Yasuharu ML, Koichi I, Nobuaki T, et al. Duration of atrial fibrillation persistence: implications for recurrence risk after catheter ablation and efficacy of additional substrate ablation. Heart Rhythm. 2024;21(6):733\u201340. https:\/\/doi.org\/10.1016\/j.hrthm.2024.01.053","journal-title":"Heart Rhythm"},{"issue":"11","key":"7706_CR23","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jacep.2019.08.021","volume":"5","author":"L Jung Myung","year":"2019","unstructured":"Jung Myung L, Jaemin S, Junbeom P, et al. The electrical isolation of the left atrial posterior wall in catheter ablation of persistent atrial fibrillation. JACC Clin Electrophysiol. 2019;5(11):1253\u201361. https:\/\/doi.org\/10.1016\/j.jacep.2019.08.021","journal-title":"JACC Clin Electrophysiol"},{"issue":"2","key":"7706_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40256-024-00691-z","volume":"25","author":"LA de Lucena","year":"2025","unstructured":"de Lucena LA, Freitas MAA, Guida CM, et al. Sacubitril-valsartan lowers atrial fibrillation recurrence and left atrial volume post-catheter ablation: systematic review and meta-analysis. Am J Cardiovasc Drugs. 2025;25(2):157\u201367. https:\/\/doi.org\/10.1007\/s40256-024-00691-z","journal-title":"Am J Cardiovasc Drugs"},{"key":"7706_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175754","volume":"952","author":"Q Li","year":"2023","unstructured":"Li Q, Fang Y, Peng DW, et al. Sacubitril\/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats. Eur J Pharmacol. 2023;952: 175754. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175754","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"7706_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1042\/CS20150469","volume":"130","author":"M Volpe","year":"2016","unstructured":"Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond). 2016;130(2):57\u201377. https:\/\/doi.org\/10.1042\/CS20150469","journal-title":"Clin Sci (Lond)"},{"issue":"2","key":"7706_CR27","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/ehf2.14239","volume":"10","author":"I El-Battrawy","year":"2023","unstructured":"El-Battrawy I, Demmer J, Abumayyaleh M, et al. The impact of sacubitril\/valsartan on outcome in patients suffering from heart failure with a concomitant diabetes mellitus. ESC Heart Fail. 2023;10(2):943\u201354. https:\/\/doi.org\/10.1002\/ehf2.14239","journal-title":"ESC Heart Fail"},{"issue":"1","key":"7706_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10557-023-07493-6","volume":"39","author":"X Zang","year":"2025","unstructured":"Zang X, Zhao Z, Chen K, et al. Evaluation of the efficacy of sacubitril\/valsartan on radiofrequency ablation in patients with hypertension and persistent atrial fibrillation. Cardiovasc Drugs Ther. 2025;39(1):97\u2013106. https:\/\/doi.org\/10.1007\/s10557-023-07493-6","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"7706_CR29","doi-asserted-by":"publisher","first-page":"338","DOI":"10.14744\/AnatolJCardiol.2020.80914","volume":"25","author":"A Kisheva","year":"2021","unstructured":"Kisheva A, Yotov Y. Risk factors for recurrence of atrial fibrillation. Anatol J Cardiol. 2021;25(5):338\u201345. https:\/\/doi.org\/10.14744\/AnatolJCardiol.2020.80914","journal-title":"Anatol J Cardiol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07706-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07706-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07706-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T22:05:26Z","timestamp":1773698726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07706-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7706"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07706-0","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"16 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Changzhou Wujin People\u2019s Hospital (No. 2021-SR-007, date of approval by the ethics committee: 2021\/10\/09).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from all enrolled patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}